KMT2A and acute myeloid leukemia: To assess the pharmacological interactions between venetoclax and KMT2A-specific drugs, incremental doses were applied based on the IC50 value of each drug (Supplementary Table S3) on SHI-1 and NOMO1 as representatives of KMT2A-AML and on HL60 as non-KMT2A-AML.